Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.
about
Treatment of relapsed and refractory multiple myelomaAmerican Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic CeEuropean perspective on multiple myeloma treatment strategies in 2014Recent advances in understanding multiple myelomaThe future of autologous stem cell transplantation in myeloma.Statistical inference methods for two crossing survival curves: a comparison of methodsAllogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party.Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT.Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I.Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.The genetic architecture of multiple myeloma.Allogeneic hematopoietic stem cell transplantation for multiple myeloma: what place, if any?Allogeneic transplantation in multiple myeloma.Immunotherapeutic approaches to treat multiple myelomaThe emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients.T cell-based targeted immunotherapies for patients with multiple myeloma.Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015.Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs.When to recommend allogeneic transplant in multiple myeloma.The role of tandem stem cell transplantation for multiple myeloma patients.Allogeneic stem cell transplantation for multiple myeloma: is there a future?Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting).Immunologic approaches for the treatment of multiple myeloma.End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma.Management of high-risk Myeloma: an evidence-based review of treatment strategies.Current Review on High-Risk Multiple Myeloma.Is immunotherapy here to stay in multiple myeloma?A View from the Plateau: Is There a Role for Allogeneic Stem Cell Transplantation in the Era of Highly Effective Therapies for Multiple Myeloma?New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting.Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma: propensity score analysis.Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution.Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation.Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma.Allogeneic hematopoietic SCT in multiple myeloma: long-term results from a single institution.Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial.The RAG Model: A New Paradigm for Genetic Risk Stratification in Multiple MyelomaSafe and effective use of outpatient non-myeloablative allogeneic stem cell transplantation for myelomaReduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival.
P2860
Q26749180-0C980693-3F20-4628-8A9B-DA8118E222F1Q26782868-CBE6B09B-98C3-47F6-9A13-4BE9D666438EQ27005966-759555E3-7152-4F02-A7E8-240B72E4C92DQ28070331-C75684A2-2C80-4BEB-8774-C49D4B0259ADQ33917164-F34450C8-CCA8-4597-B10D-37DE2133697FQ35547966-40810ECD-BB0F-4A0B-80DF-2BFE67866C73Q36000415-1D29FD7C-9EC5-4CE0-B58E-00E1E3216518Q36031316-1F67ACDE-8905-43CF-9D28-C02BCA2C0F6DQ36413676-A4CBA28C-FDA9-49C0-9333-CCA3726BE51FQ37037265-5D7AA47D-0AED-4899-AF39-3E3606C28101Q37552008-B5525700-90B3-413C-8F97-60DACD1AAF53Q37718836-EA3E39E2-0441-4CC6-BB57-44AD8680B737Q38154518-45EDBE04-33C7-45A9-ABBD-5D40BBDB9BE4Q38162280-99386269-D424-40BD-A961-D94405447B6EQ38171067-4B070F61-A304-4460-A558-30DDB7B5AEE1Q38182679-9C549DB5-2CF7-4C9E-9095-05B8496B17B7Q38246639-71C1C3F8-5100-4044-8E4C-8D056ECD913BQ38387292-F3365476-48ED-4625-8651-93F6FD24A79CQ38417073-D73DAE4D-47A1-4256-87A7-DD0DC0334320Q38491721-13E49F3B-7546-4E32-A247-5CC3267FB8DDQ38677358-EDA1EDAF-D72F-4DB3-8B7A-876F00D6753DQ38685796-B5D333EF-9FCE-4526-AF7A-23C00D35CECAQ38688055-F3A5F82E-BF31-4E6D-BC5B-045D2888177AQ38692244-3765010E-18FE-4F3B-8FE6-6DF4E9485557Q38732370-ED7A13D1-1209-4555-B87F-E24E2417E2B4Q38874675-12CE5B47-D20C-43F9-B4F0-7CF423B84BF2Q38895167-C0DA47FE-5A03-463D-8822-E3407BB11426Q39084427-92038237-1834-4DF5-B656-E7E41B5D7DE3Q39112978-67208DE6-574E-4BD7-A93A-5B442D0E5B37Q39307476-40ABC2AA-2CE9-48D2-8E68-3BC9B09D91F0Q39369772-570119F0-5FC3-40E7-9F12-16B301B3319FQ39933810-C91E40F6-5EDD-4513-A122-76EA45601515Q40827148-253DE648-C2F2-48DF-969D-29C1EF243452Q41031177-49DA6762-7F06-4831-9A6A-56FA7EF64E0FQ41179473-5D6C794D-0BDB-4D5E-B736-51956877F207Q41522018-95340056-F497-44BF-91FB-B35265775BD7Q41525599-BDA5A011-A6F6-4A13-8E1D-4863F0CA7901Q42055422-7C9666B6-C75B-44C0-AD9E-BA10002AD09FQ42616592-963539E3-3BAE-4957-BF59-94ACF8EA904DQ43146952-885276AF-A75A-4921-8C0D-69EE72107E3C
P2860
Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Autologous/reduced-intensity a ...... ts of the EBMT-NMAM2000 study.
@en
Autologous/reduced-intensity a ...... ts of the EBMT-NMAM2000 study.
@nl
type
label
Autologous/reduced-intensity a ...... ts of the EBMT-NMAM2000 study.
@en
Autologous/reduced-intensity a ...... ts of the EBMT-NMAM2000 study.
@nl
prefLabel
Autologous/reduced-intensity a ...... ts of the EBMT-NMAM2000 study.
@en
Autologous/reduced-intensity a ...... ts of the EBMT-NMAM2000 study.
@nl
P2093
P50
P1433
P1476
Autologous/reduced-intensity a ...... lts of the EBMT-NMAM2000 study
@en
P2093
Angelo Michele Carella
Anja van Biezen
Astrid Gruber
Bo Björkstrand
Curly Morris
Dietger Niederwieser
EBMT Chronic Malignancies Working Party Plasma Cell Disorders Subcommittee
Gösta Gahrton
Hildegard Greinix
Kristina Friberg
P304
P356
10.1182/BLOOD-2012-11-469452
P407
P577
2013-03-12T00:00:00Z